Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Hexarelin | Tesamorelin | |
|---|---|---|
| Category | Peptides | Peptides |
| Standard Dose | Research indicates 100-200 mcg administered 1-2 times daily via subcutaneous injection. | Research indicates 2 mg administered once daily via subcutaneous injection (FDA-approved dose for HIV lipodystrophy). |
| Timing | On empty stomach, bedtime preferred. Avoid prolonged continuous use due to rapid desensitization. | Morning administration on empty stomach. Consistent daily timing recommended. |
| Cycle Duration | 4-8 week cycles maximum, then 4+ week break. Hexarelin desensitizes faster than other GHRPs. | 26+ weeks in clinical trials. Long-term use is common; effects are not sustained after discontinuation. |
| Evidence Level | moderate_human | Strong (FDA-approved indication), Moderate (longevity) |
Hexarelin (Examorelin) is a synthetic hexapeptide GHS-R1a agonist and the most potent synthetic GH secretagogue by peak GH release. It stimulates GH release through both pituitary ghrelin receptors and hypothalamic pathways, with mechanisms involving regulation of GHRH and somatostatin. Hexarelin also demonstrates significant cardiac benefits through activation of cardiac GHS-R1a receptors, protecting against ischemia-reperfusion injury and reducing cardiac fibrosis via the CD36 scavenger receptor pathway.
Research indicates 100-200 mcg administered 1-2 times daily via subcutaneous injection.
On empty stomach, bedtime preferred. Avoid prolonged continuous use due to rapid desensitization.
4-8 week cycles maximum, then 4+ week break. Hexarelin desensitizes faster than other GHRPs.
Tesamorelin is an FDA-approved synthetic 44-amino acid GHRH analog with a trans-3-hexenoic acid modification at the N-terminal tyrosine that confers resistance to DPP-IV degradation. It binds GHRH receptors on anterior pituitary somatotrophs, stimulating endogenous GH production and secretion while maintaining pulsatile release patterns. Tesamorelin selectively reduces visceral adipose tissue (15-20% reduction in trials) while preserving subcutaneous fat, and markedly increases plasma GH and IGF-1 levels with once-daily dosing.
Research indicates 2 mg administered once daily via subcutaneous injection (FDA-approved dose for HIV lipodystrophy).
Morning administration on empty stomach. Consistent daily timing recommended.
26+ weeks in clinical trials. Long-term use is common; effects are not sustained after discontinuation.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →